Loading
Zanidatamab zovodotin joined the two-armed HER2 antibody zanidatamab to a cell-killing payload. It was tested in early trials in HER2-expressing cancers; the plain antibody went on to approval, the conjugate did not progress beyond phase 1.
Zanidatamab zovodotin (ZW49) was Zymeworks' antibody-drug conjugate built on zanidatamab, the biparatopic HER2 antibody now approved as Ziihera. Binding two HER2 epitopes was intended to make the receptor cluster and internalise faster, delivering more of the auristatin payload into HER2-expressing tumour cells, including those with lower HER2 expression.
It was given intravenously in a phase 1 dose-escalation study across HER2-expressing solid tumours, including breast and gastro-oesophageal cancers. The programme was not advanced into registrational trials; it is named on the HER2-positive breast cancer page as one of the next-generation and biparatopic HER2 conjugates that followed trastuzumab deruxtecan.
The biparatopic antibody zanidatamab, which binds two different HER2 domains at once, carried an auristatin payload; the dual binding clusters HER2 and drives the conjugate into the cell where the payload is released. Connects to HER2.
1.Zanidatamab zovodotin's antibody arm binds HER2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Zanidatamab zovodotin" OR ABSTRACT:"Zanidatamab zovodotin" OR TITLE:"ZW49" OR ABSTRACT:"ZW49") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Zanidatamab zovodotin, not a curated reading list.
Shares Trastuzumab deruxtecan, HER2 and the tag subtype-drugs-wave.
Shares Antibody-drug conjugate (ADC) and the tag subtype-drugs-wave.
Shares Zanidatamab, Trastuzumab deruxtecan, HER2, Gallbladder cancer.
Shares Trastuzumab deruxtecan, HER2, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, HER2, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Shares Zanidatamab, Trastuzumab deruxtecan, HER2, Gastric & gastro-oesophageal junction cancer.
Shares Trastuzumab deruxtecan, HER2, HER2-positive breast cancer, Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, HER2, Antibody-drug conjugate (ADC).